National Comprehensive Cancer Network

NCCN Oncology Research Program (ORP)
NCCN ORP Recent News
NCCN ORP Affiliate Research Consortium
NCCN ORP Scientific Publications
NCCN ORP for Industry
NCCN ORP Investigator Steering Committee
NCCN ORP Testimonials
NCCN Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
NCCN ORP Grant History
NCCN Informed Consent Language Database
NCCN Specialized Imaging Research Consortium™ (SIRC)
NCCN ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

CML Guidelines Updated

The NCCN Clinical Practice Guidelines in Oncology™ for Chronic Myelogenous Leukemia have been updated.

The updates include the addition of PEG-interferon (PEG-IFN) as an alternative to IFN in specified circumstances. Also, for patients not responding to treatment with imatinib, an evaluation of drug-drug interactions was added to the assessment for patient compliance.

The FDA black box warning for nilotinib was added as an attachment to alert clinicians of important considerations with the use of nilotinib. In addition, some of the response categories were reclassified based upon treatment recommendations.